Reports on HGV RNA in Cryptogenic FH
| Reference . | Serum HGV RNA [no. (+)/ total no.] . | % Positive . | HGV in Liver . | Transfusion or Other Risk Factors4-150 . |
|---|---|---|---|---|
| Heringlake et al25 | 5/10 | 50 | ND | Unknown |
| Kuroki et al42 | 0/7 | 0 | ND | 0/7 |
| Sallie et al32 | 0/20 | 0 | 0/20 | Unknown |
| Yoshiba et al33 38 | 6/16 | 38 | ND | 1/16 |
| Fukumoto et al37 | 1/12 | 8 | ND | 2/12 |
| Haydon et al36 | 5/23 | 22 | ND | 5/5 |
| Tanaka et al23 | 2/19 | 11 | ND | 9/19 |
| Moaven et al24 | 0/144-151 | 0 | ND | Unknown |
| Saiz et al22 | 2/19 | 11 | ND | Unknown |
| Total | 21/140 | 15.6 ± 18 | 0/20 | 17/59 |
| Reference . | Serum HGV RNA [no. (+)/ total no.] . | % Positive . | HGV in Liver . | Transfusion or Other Risk Factors4-150 . |
|---|---|---|---|---|
| Heringlake et al25 | 5/10 | 50 | ND | Unknown |
| Kuroki et al42 | 0/7 | 0 | ND | 0/7 |
| Sallie et al32 | 0/20 | 0 | 0/20 | Unknown |
| Yoshiba et al33 38 | 6/16 | 38 | ND | 1/16 |
| Fukumoto et al37 | 1/12 | 8 | ND | 2/12 |
| Haydon et al36 | 5/23 | 22 | ND | 5/5 |
| Tanaka et al23 | 2/19 | 11 | ND | 9/19 |
| Moaven et al24 | 0/144-151 | 0 | ND | Unknown |
| Saiz et al22 | 2/19 | 11 | ND | Unknown |
| Total | 21/140 | 15.6 ± 18 | 0/20 | 17/59 |
Abbreviation: ND, not done.
Including but not limiting to recent or remote history of hepatitis; transfusion of whole blood, platelets, or fresh plasma; intravenous drug use; and health-related occupation.
Eight of the 11 patients who went on to liver transplantation became HGV RNA positive postoperatively, in association with perioperative blood transfusions.